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Cystic echinococcosis is a zoonotic infection caused by the larval stage of the cestode Echinococcus granulosus. Chemotherapy
currently employs benzimidazoles; however, 40% of cases do not respond favorably. With regard to these difficulties, novel ther-
apeutic tools are needed to optimize treatment in humans. The aim of this work was to explore the in vitro and in vivo effects of
tamoxifen (TAM) against E. granulosus. In addition, possible mechanisms for the susceptibility of TAM are discussed in relation
to calcium homeostasis, P-glycoprotein inhibition, and antagonist effects on a putative steroid receptor. After 24 h of treatment,
TAM, at a lowmicromolar concentration range (10 to 50M), inhibited the survival of E. granulosus protoscoleces and metaces-
todes. Moreover, we demonstrated the chemotherapeutic and chemopreventive pharmacological effects of the drug. At a dose
rate of 20 mg/kg of body weight, TAM induced protection against the infection in mice. In the clinical efficacy studies, a reduc-
tion in cyst weight was observed after the administration of 20 mg/kg in mice with cysts developed during 3 or 6 months, com-
pared to that of those collected from control mice. Since the collateral effects of high TAM doses have been largely documented
in clinical trials, the use of low doses of this drug as a short-term therapy may be a novel alternative approach for human cystic
echinococcosis treatment.
Human cystic echinococcosis (CE), or hydatidosis, is a zoo-notic infection caused by the larval stage of the cestode Echi-
nococcus granulosus. The metacestode develops as a unilocular cyst
that consists of an inner germinal layer with totipotent cells which
produce brood capsules with multiple protoscoleces by asexual
division, supported by a laminated acellular membrane, named
the laminar layer. The treatment options for CE are surgery and/or
chemotherapy, depending on the location, state, and number of
the cysts. The only two drugs licensed to date are the benzimid-
azole carbamate derivatives albendazole and mebendazole (1).
Therefore, a search for novel candidates for the treatment of hy-
datidosis has been proposed. The performances of potential ther-
apeutic compounds have been investigated, applying antimicro-
bial and anticancer agents in in vitro and in vivo assays (2).
The effects of several drugs inhibiting proliferation of cancer
cells were assayed on Echinococcus metacestodes and protosco-
leces (3–5). Spicher et al. (4) demonstrated the in vitro and in vivo
effects of an endogenous metabolite of estrogen, 2-methoxyestra-
diol, either alone or combined with albendazole, against Echino-
coccus multilocularis and E. granulosus. Furthermore, the isofla-
vone genistein and the genistein derivative Rm6423 exhibited
profound in vitro activities against the mentioned parasites (3).
The cytostatic drug imatinib had drastic effects on the in vitro
development and survival of E. multilocularis (5).
Tamoxifen (TAM) is a competitive antagonist of the estrogen
receptor alpha (ER), classified as a nonsteroidal selective estro-
gen receptor modulator (SERM), widely used for treating primary
breast cancer in premenopausal women and gynecomastia in men
receiving hormonal therapy for prostatic carcinoma (6). TAM and
its bioactive metabolites, 4-hydroxytamoxifen (4-OH-TAM) and
N-desmethyl tamoxifen (ND-TAM), inhibit proliferation and in-
duce apoptosis in several types of ER-positive and ER-negative
breast cancer cells, rat mammary tumors, and other cancer types
(7, 8). Interestingly, this antiestrogenic drug has also proved to be
effective against several protozoan parasites, including Leishma-
niamajor, Leishmania braziliensis, Leishmania chagasi, Leishmania
amazonensis, and Trypanosoma cruzi (9–11). Furthermore, the ef-
fect of TAM on cestode parasites has been studied in Taenia cras-
siceps and Taenia solium (12, 13). In fact, TAM inhibits T. crassi-
ceps and T. solium proliferation and in vitro viability, whereas it
induces protection against the infection in murine and hamster
models, respectively (12, 13). Antiestrogenic drugs have never
been studied in E. granulosus.
Estrogen receptors have an evolutionary conserved modular
structure. It consists of a DNA-binding domain (DBD), a nuclear
localization signal (NLS), and a ligand-binding domain (LBD) at
the C terminus. The LBD of ER has been crystallized with 17-
estradiol (E2), diethylstilbestrol (DES), and the SERMs TAM and
raloxifene (14). The bulky side chain of these SERMs prevents
sealing of the LBD, and this produces antiestrogenic action (15,
16). Typical nuclear receptors (NR) have been identified in Echi-
nococcus spp. (ortholog of SmFTZ-F1) with the highest homolo-
gies (approximately 26% identical amino acids) of all identified
cestode NR to the LBDs of vertebrate ERs (17).
TAM also acts via an estrogen receptor-independent mecha-
nism. It has a wide range of effects on mammalian cell physiology,
such as induction of intracellular calcium release, apoptosis, and
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autophagy. Moreover, it possesses antioxidant and antiangiogen-
esis properties (18). Consistent with this wide range of cellular
effects, TAM has been shown to target mammalian proteins such
as calmodulin (CaM), protein kinase C, phospholipase C, phos-
phoinositide kinase, P-glycoprotein (Pgp), and swelling-induced
chloride channels (19).
Here, we report data showing the in vitro activity of TAM
against protoscoleces and metacestodes and the in silico analysis of
a possible interaction with a putative steroid receptor (SR). More-
over, we investigated the chemoprophylactic and clinical efficacy
of TAM in mice infected with E. granulosus.
MATERIALS AND METHODS
Chemicals. Culture-grade tamoxifen citrate was obtained from Sigma-
Aldrich (USA). TAM was kept as a 100 mM stock solution in dimethyl
sulfoxide at 20°C for in vitro assays. Dilutions were prepared in medium at
concentrations of 5 to 200 M. For in vivo experiments, oily solutions of
TAM were prepared by taking aliquots from fresh alcoholic stock solu-
tions, and adding the required volume of corn oil (Sigma-Aldrich) and
maintained under refrigeration (3 to 5°C).
In vitro culture of E. granulosus protoscoleces and drug treatment.
Protoscoleces were removed under aseptic conditions from hydatid cysts
of infected cattle slaughtered in two abattoirs located in the southeast of
Buenos Aires province, Argentina. The area where the cattle came from is
known to include only the G1 strain of E. granulosus. Viable, motile, and
morphologically intact protoscoleces (n  3,000) were cultured using
medium 199 (Gibco) supplemented with antibiotics (20). Protoscoleces
were incubated in 24-well culture dishes in the presence of increasing
concentrations (5 to 100 M) of TAM up to 7 days. Viability assays were
performed daily until the death of all parasites (20). Five experiments were
performed in triplicate, and results are expressed as the mean percentages
of reduction of parasite numbers compared with those in untreated con-
trol wells. For scanning electron microscopy (SEM), samples were taken
every 12 h and processed (20).
Detection of the cytosolic calcium levels in E. granulosus protosco-
leces. Changes in cytosolic free Ca2 concentrations ([Ca2]i) were fluo-
rometrically monitored using a Fluo-3 acetoxymethyl ester(Fluo-3-AM)
probe (20). The experiments were carried out with 5 103 protoscoleces,
which were incubated with 10, 25, and 50 M TAM for 2 h. Pretreat-
ments with 1 mM EGTA or 100 M 1,2-bis(2-aminophenoxy)ethane-
N,N,N=,N=-tetraacetic acid acetoxymethyl ester (BAPTA-AM) or both
calcium chelators were carried out for 15 min. Then, fluorescence was
registered with a spectrofluorimeter (model F-4500; Hitachi). Excitation
was provided by the 488-nm line of a krypton-argon laser, and the emitted
fluorescence was collected using band-pass filters (505 to 530 nm). At the
end of registration, 1 mM EGTA plus 100 M BAPTA-AM was added to
chelate Ca2. After 5 min, fluorescence was measured again every 1 min
for 30 min (Fmin, total fluorescence of dye in the absence of free Ca
2).
Each experiment was individually corrected for autofluorescence, and
untreated controls were included in each replication.
Ethics statement. Animal procedures and management protocols
were carried out in accordance with the 2011 revised form ofTheGuide for
the Care and Use of Laboratory Animals published by the U.S. National
Institutes of Health. Unnecessary animal suffering was avoided through-
out the study.
Mouse infection and procedures for in vitro incubation of cysts.
Infection of mice and obtaining of cysts were carried out as previously
described (21). Briefly, female CF1 mice (body weight, 25  5 g) were
infected by intraperitoneal infection of 1,500 protoscoleces in 0.5 ml of
medium 199 to produce experimental secondary hydatid disease. Animals
were housed in a temperature-controlled (22  1°C), light-cycled (12-h
light/dark cycle) room. Food and water were provided ad libitum. At 6
months postinfection (p.i.), mice were euthanized, and necropsy was car-
ried out immediately thereafter. At necropsy, the peritoneal cavity was
opened, and the hydatid cysts were carefully removed.
Groups of 10 to 15 E. granulosus murine cysts with diameters between
3 and 5 mm were incubated in Leighton tubes in the presence of increasing
concentrations (5 to 100M) of TAM. Metacestode viability was assessed
daily through an inverted light microscope (until the viability control was
	90%, approximately 6 days). The criteria for cyst viability assessment
included the loss of turgidity and the collapse of the germinal layers. Each
experiment was assayed for three replicates and repeated three times.
Analysis of E. granulosus Pgp and tegumental gamma-glutamyl-
transpeptidase activities of in vitro TAM-treated protoscoleces and
metacestodes. Pgp transport activity was measured in the absence and
presence of 25M TAM from fresh samples of protoscoleces (n 1,000)
and intact metacestodes (n  10) on 96-well plates using a calcein AM
assay (Molecular Probes, USA) (22). Each experiment was assayed for
three replicates and repeated three times. Protoscoleces were also imaged
with an inverted confocal laser scanning microscope (confocal micro-
scope C1; Nikon).
Gamma-glutamyl-transpeptidase (GGT), associated with damage of
the internal tegument, was determined following the Szasz method from
protoscoleces and metacestodes (23).
Chemoprophylactic efficacy study. Experimental animals were in-
fected and housed as described above. At the time point of infection, 20
CF-1 mice were allocated into 1 of 2 experimental groups (10 animals/
group): (i) an unmedicated control group, receiving corn oil as a placebo,
and (ii) a treated group, receiving TAM dissolved in corn oil. In the che-
moprophylactic efficacy study, treatments were performed every 48 h (40
doses) by intragastric administration (0.3 ml/animal) at the dose rate of 20
mg/kg of body weight. Six months after infection, the mice were eutha-
nized, and necropsies were carried out immediately thereafter.
Clinical efficacy study.Two different experimental designs were used.
(i) Experiment 1. At 6 months p.i., mice were allocated to one of two
experimental groups (10 animals/group): (a) an unmedicated control
group, receiving corn oil as a placebo, and (b) a TAM suspension-treated
group (experiment 1 [E1]), receiving a dose rate of 20 mg/kg every 48 h
(40 doses).
(ii) Experiment 2.At 3 months p.i., mice were allocated to one of three
experimental groups (10 animals/group): (a) an unmedicated control
group, receiving corn oil as a placebo, (b) a TAM suspension-treated
group (experiment 2a [E2a]), receiving 20 mg/kg every 48 h (40 doses),
and (c) a TAM suspension-treated group (experiment 2b [E2b]), receiv-
ing 100 mg/kg/day every 48 h (16 doses). In all cases, the treatments were
performed by intragastric administration (0.3 ml/animal). The final dose
received by mice in group E2b was double the final dose administered to
groups E1 and E2a. At the end of the treatment period, the animals were
euthanized, and necropsies were carried out immediately thereafter.
Determination of efficacy of in vivo treatments. At necropsy in both
the prophylactic and efficacy studies, the peritoneal cavity was opened,
and the hydatid cysts were carefully removed. The weight of the cysts
collected from each individual animal was recorded using an analytical
balance. The efficacy of treatments (based on the weights of the cysts from
infected mice) was calculated using the formula (mean weight of the con-
trol group
mean cyst weight of the treated group)/mean cyst weight of
the control group  100. Samples of cysts recovered from each mouse
were processed for SEM or transmission electron microscopy (TEM) as
described by Elissondo et al. (21).
Analysis of TAM and itsmetabolites. A spectrophotometric method,
based on the formation of a chloroform-soluble ion-association complex
between TAM and the dye alizarin red-S in acidic medium, was used for
the determination of intracystic TAM. Cystic samples were obtained from
the sacrificed animals. Cystic liquids were extracted, and the precipitated
protein was removed by centrifugation at 2,000  g for 15 min. The
supernatants were transferred to sample vials, and the vials were capped
and stored at
20°C until analysis by the colorimetric method (24). The
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colored complexes between the dye, TAM, and its metabolites were deter-
mined at 440 nm.
Expression and sequence analysis of Echinococcus SR. A BLASTp
search for ER homologs in the E. granulosus genome database (http:
//www.sanger.ac.uk/Projects/Echinococcus) was carried out using Homo
sapiens ER (GenBank accession no. NP_000116) and ER (GenBank
accession no. AAC05985) as queries. These data allowed the identification
of an ortholog of EmuJ_000814300 and SmFTZ-F1, whose predicted open
reading frame encodes a putative E. granulosus SR (EgrG_000814300 in-
cluded in the EgG_scaffold_0001 at position 7377598 to 7382189) named
E. granulosus SR (17). Specific primers for the putative E. granulosus sr1
gene were designed (srFw, 5=-ATTTGCGGGGACAAGATATCGGGTTA
TCAT-3=, and sr-Rv, 5=-CAATTTTGAAGAAGCAATATCTGATCATCT
GT-3=) for its amplification. Total RNA extractions from E. granulosus
protoscoleces and metacestodes were performed (23). The partial-length
amplified cDNAs were obtained through direct sequencing of a PCR frag-
ment (897 bp).
Sequence alignments were generated with the ClustalX software pro-
gram, and modeling of the E. granulosus SR tertiary structure was ob-
tained from the deduced primary structure using GenTHREADER (http:
//bioinf.cs.ucl.ac.uk/psipred/). Predictions of NLSs and hydrophobic
cores were analyzed with cNLS Mapper (http://nls-mapper.iab.keio.ac.jp
/cgi-bin/NLS_Mapper_form.cgi) and ProtScale (http://web.expasy.org
/protscale).
Statistics. Data within experiments were compared, and the signifi-
cance was determined using the Student t test and nonparametric Mann-
Whitney test. All data are shown as arithmetic means standard errors of
the mean (SEM), and P values for each assay are indicated.
RESULTS
TAM treatment increases intracellular calcium in E. granulosus
protoscoleces. TAM exposure (20 M) increased free [Ca2]i
7-fold over a 2-h observation period compared with that in the
controls (Fig. 1A). To determine whether the TAM-induced in-
crease was from the intracellular stores or the extracellular space,
we pretreated parasites with BAPTA-AM (a membrane-perme-
able calcium chelator) and EGTA (an extracellular chelator) im-
mediately prior to addition of the drug. The fluorescence de-
creased to about control values only with both chelators in the
medium, indicating that these drugs were able to release [Ca2]i
from extracellular and intracellular stores in E. granulosus. Nor-
malization of cytosolic calcium was also consistently delayed in
TAM-treated cultures compared with that in the controls (data
not shown).
TAM inhibitsE. granulosusPgp activity in protoscoleces and
metacestodes. Pgp activity is inversely proportional to the accu-
mulation of intracellular fluorescent calcein. Control protosco-
leces and metacestodes (sections and intact cysts) showed basal
FIG 1 In vitro effect of TAM treatment in Echinococcus granulosus protosco-
leces and metacestodes. (A) Determination of changes in the cytosolic free
Ca2 concentration ([Ca2]i) from control protoscoleces incubated with buf-
fer (C, control) or with 20 M TAM for 2 h and then loaded with Fluo-3-AM
(s). Pretreatments with 1 mM EGTA plus 100 M BAPTA-AM () for 15
min were carried out before the Fluo-3-AM incubations. Data are the means
SD from five independent experiments. (B) Relative fluorescence levels in
protoscoleces (PTS) and dissected metacestodes (MTC) in the presence of 20
M TAM compared with the control levels. Treated parasites showed a signif-
icant increase in fluorescence (*, P	 0.005) with respect to that of the control,
indicating that TAM is a Pgp inhibitor. The values represent means standard
deviations. (C) Confocal imaging revealed calcein accumulation in the tegu-
ment and suckers. Shown are light field (a and c) and fluorescence field (b and
d) photomicroscopy; control protoscoleces (a and b) and protoscoleces
treated with TAM (c and d). Bar, 50 m.
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and stable E. granulosus Pgp activity, because the calcein-AM was
extruded from the cells (typically 75  5 fluorescent units [FU]
and 125 15 FU, respectively) (Fig. 1B). In the presence of 20M
TAM, protoscoleces and metacestodes increased 10- and 3-fold in
relative FU, respectively, over controls (Fig. 1B). Pgp activity was
detected by confocal microscopy, particularly in suckers and teg-
ument (Fig. 1C).
In vitro activity of TAM against E. granulosus protoscoleces
and metacestodes. Viability decreased as a function of drug con-
centration in both protoscoleces and metacestodes (Fig. 2 and 3).
TAM had an effect from a concentration of 10 M and at 50 M
reduced the viability of treated protoscoleces to 45% 2.3% after
24 h (Fig. 2A). The protoscolex mortality rate was 100% after
incubation for 7 days with 20 M TAM (Fig. 2B). Untreated pro-
toscoleces remained at least 99% 1.0% viable during the com-
plete experiment. After 24 h of treatment, the ultrastructure of
protoscoleces incubated with 20M TAM showed significant dif-
ferences compared with that of control samples (Fig. 2C). Proto-
scoleces showed the a complete alteration of the tegument, shed-
ding of microtriches, loss of hooks, and contraction of the soma
region. After 24 h or 72 h, metacestodes incubated with 50 and 20
M TAM presented detachment of the germinal layer in 100% of
cysts (Fig. 3). The calculated 50% inhibitory concentration (IC50)
against metacestodes was 18 3 M (Fig. 3A, inset).
FIG 2 In vitro TAM treatment of Echinococcus granulosus protoscoleces. (A)
Protoscolicidal activity of TAM from cultures maintained for 24 h. Bars show
means standard errors from five independent experiments. (B) Long-term
effect of 20 M TAM on E. granulosus protoscolex viability over 7 days. Each
point represents the mean percentage of vital protoscoleces from three differ-
ent experiments. ***, Statistically significant difference (P 	 0.05) from the
corresponding control. (C) Ultrastructural changes of protoscoleces detected
by SEM after incubation with TAM (20 M, 48 h). Control (a, invaginated
protoscolex; b, evaginated protoscolex) and TAM-treated (c and d) protosco-
leces are shown. Note the extensive drug-induced damage with contraction of
the soma region, alterations in the tegument, and loss of rostellar hooks and
microtriches in the scolex region. Bars, 20 m (a, b, and d) and 50 m (c). rc,
rostellar cone; su, suckers; bo, body.
FIG 3 In vitro TAM treatment of Echinococcus granulosus metacestodes. (A)
Metacestode viability measured on the basis of vesicle integrity. The IC50 is
shown in the inset. (B) Macroscopic photographs showing the detachment of
the germinal layer from the laminar layer of the metacestodes (20 M, 48 h).
Control (C, without morphological changes) and treated (TAM) metacestodes
show increased permeability (culture medium inside cysts) and collapsed ger-
minal membranes (arrows).
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The ultrastructural alterations were accompanied by the re-
lease ofE. granulosusGGT into the medium supernatant in a dose-
dependent manner (data not shown). An increase in the E. granu-
losus GGT activity in the culture supernatants of cysts and
protoscoleces incubated in vitro with 20 M TAM was detected.
After 24 h of incubation, total E. granulosus GGT activity in the
protoscolex culture supernatants was measured (42  5 nmol
min
1 mg
1). This value was two times higher than that in meta-
cestodes (18 5 nmol min
1 mg
1). E. granulosus GGT activity
was barely detectable in control supernatants.
Chemoprophylactic efficacy study. All of the infected mice
from the untreated control group (10/10) developed metacestodes
in the abdominal cavity, whereas in 4 out of the 10 treated mice,
the infection did not progress. Statistically significant differences
(P 	 0.05) were observed in the weights of the cysts recovered
from untreated mice (7.2 3.4 g) compared with those from the
TAM-treated group (0.64 0.35 g) (Fig. 4A).
All cysts removed from control mice appeared turgid, showing
no observable collapse of the germinal layer, and no changes in
ultrastructure were detected by SEM (Fig. 4Ba). TEM analysis of
cysts recovered from the untreated control group revealed the
typical features of E. granulosus metacestodes, with a distinct acel-
lular outer laminated layer and a germinal layer without altera-
tions (Fig. 4Bc). In contrast, the ultrastructural study of cysts de-
veloped in mice treated with TAM suspension revealed changes in
the germinal layer. Regarding the ultrastructural study with SEM,
only cell debris was observed (Fig. 4Bb). TEM analysis of cysts
from treated mice revealed completely damaged germinal layers
with internal tissue extensively distorted, vacuolated areas, and
numerous lipid droplets (Fig. 4Bd).
Clinical efficacy study. All infected animals involved in the
efficacy study developed cysts in their abdominal cavity. All treat-
ments resulted in statistically significant reductions in the cyst
weights compared with those obtained from unmedicated mice
(E1 and E2) (Fig. 5A).
FIG 4 Chemoprophylactic activity of TAM during Echinococcus granulosus
cyst development. (A) Box plot showing the comparative distribution of the
weight (g) of the cysts recovered from untreated and TAM-treated (20 mg/kg)
mice. A significant cyst weight reduction (P	 0.005) was achieved in treated
animals. (B) Representative SEM (a and b) and TEM (c and d) images of
hydatid cysts recovered from untreated control mice (a and c) compared with
those from TAM-treated mice (b and d). LL, laminar layer; MT, microtriches;
DC, distal cytoplasm; GL, germinal layer.
FIG 5 In vivo TAM treatment of Echinococcus granulosus-infected mice. (A)
Box plots indicate the distribution of cyst weights (g) in the different treatment
groups. Significant reductions of recovered parasite weights in relation to
those in the control groups were achieved. (B) Representative images obtained
by SEM of cysts from TAM-treated mice. (a) Control after 6 months p.i.; (b)
TAM-treated mice from E1; (c) E2a; (d) E2b. (C) Intracystic concentrations of
TAM and its metabolites from the experiments whose results are presented in
panel B.
Nicolao et al.
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When the treatment was initiated after 6 months p.i. (E1), the
efficacy of TAM was 61%. TAM treatment resulted in a reduction
in the cyst weights (4.9 1 g) compared with those obtained from
unmedicated mice (12.5 6.2 g). This reduction was statistically
significant (P	 0.01). On the other hand, during E2, TAM treat-
ment was initiated after cysts developed for 3 months. Two differ-
ent therapeutic schemes were developed: 20 mg/kg every 48 h
(E2a) and 100 mg/kg every 48 h (E2b). This 5-fold increase in the
dose improved the efficacy of the treatment (83% versus 68%),
but no statistically significant differences were found between the
weights of cysts recovered from the two groups (P  0.05) (Fig.
5A). There were statistical differences (P 	 0.05) between the
weight of cysts recovered from the unmedicated group (6.3 2 g)
and those from the E2a and E2b treated groups (2.0 0.92 g and
1.1 0.6 g, respectively).
All cysts removed from the unmedicated control mice at 3 or 6
months p.i. appeared turgid, showing no observable collapse of
the germinal layer, in which no alteration in ultrastructure was
observed by SEM (Fig. 5Ba). On the other hand, the ultrastruc-
tural study of cysts developed in mice treated with TAM revealed
alterations in the germinal layer. However, the extent of damage
appeared to be broader when the treatment was initiated at 3
months p.i. (E2) (Fig. 5Bc and Bd). Moreover, a complete loss of
cells from the germinal layer of cysts was observed with the highest
dose (100 mg/kg) (Fig. 5Bd).
TAM and its metabolites were detected in cysts obtained from
treated mice (Fig. 5C). A dose-concentration relationship was de-
tected for E2b (100 mg/kg, 20 3 g/ml) versus E2a (20 mg/kg,
12 2 g/ml).
In silico analysis of putative Echinococcus SR. Reverse tran-
scription (RT)-PCR analysis showed that E. granulosus sr1 is ex-
pressed in control conditions from protoscoleces and metaces-
todes (data not shown). E. granulosus SR is a typical NR (Fig. 6). It
contains a DBD (residues 340 to 550) with two highly conserved
zinc finger motifs (CI and CII, called the P and D boxes) respon-
sible for the sequence-specific DNA recognition and the dimeriza-
tion (Fig. 6A). The hinge region between the DBD and the LBD is
a poorly conserved sequence in E. granulosus SR as in all NR, due
FIG 6 Sequence analysis of Echinococcus granulosus steroid receptor (Eg-SR). Multiple sequence alignment of DBD (A) and LBD (B) among invertebrate and
vertebrate species: Aplysia californica (Ac-ER) (NP_001191648, Mollusca) and Homo sapiens (Hs-ER) (NP_000116, Vertebrata). Consensus is indicated in the
last line: total (capital letters), partial (lowercase letters), conservative changes (asterisks), and nonconservative substitutions (dots). Nuclear localization signals
(NLS) are indicated with gray-shaded boxes. In the N-terminal DBD, the alignments of highly conserved zinc finger motifs (CI [C-X2-C-X13-C-X2-C-] and CII
[C-X5/10-C-X9-C-X2-C]; dashed-line boxes) and the cysteine residues (arrows) are indicated. The CaM binding region is underlined, and three lysine residues
involved in direct association with the CaM ER are indicated with arrowheads. In the C-terminal LBD, the hydrophobic portion involved in the ligand interaction
is boxed, the conserved NR box motifs (residues shown with pound signs) and the key polar amino acids (residues shown with ! in H. sapiens ER corresponding
to E353, R394, and H524) are indicated.
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to its function as a flexible region. In H. sapiens ER, this region is
involved in CaM binding (residues 248 to 317), and it showed 38%
similarity to E. granulosus SR (residues 430 to 500). The C-termi-
nal LBD of E. granulosus SR (residues 580 to 770 compared with
residues 340 to 530 of H. sapiens ER) is the most highly hydropho-
bic portion of the protein in agreement with orthologs (Fig. 6B).
This region contains two partially conserved motifs (LXXLL,
named the NR box) and key polar amino acids, which might be
involved in hydrogen bonds with 17-estradiol and estrogen de-
rivates.
DISCUSSION
E. granulosus and E. multilocularis metacestodes exhibit tumor-
like properties, as reflected by their seemingly unlimited growth
and proliferation potential and their abilities to modulate the im-
mune response and to form metastases (4). In this study, we dem-
onstrate that TAM exhibits promising in vitro and in vivo activity
against E. granulosus.
TAM treatment of protoscoleces (50 M) and metacestodes
(20 M) resulted in the killing of 50% of parasites after 24 h
compared with those in the controls (Fig. 2 and 3). As assessed by
E. granulosus GGT activity, the protoscolex tegument was com-
pletely contracted (Fig. 2C), and the cyst germinal layer was de-
tached (Fig. 3B). Taken together, all of the above results showed
that 20M TAM has severe effects on the in vitro survival of the E.
granulosus larval stage in a time-dependent manner, demonstrat-
ing the potent effect of the parental drug. While TAM exerts its
toxic effects within a short time (24 to 48 h), other previously
characterized drugs such as benzimidazoles (21, 25) and praziqu-
antel (25) presented pharmacological effects only after 5 to 12 days
of treatment. In future studies, we will assay the effect of TAM at
shorter times (minutes) in order to evaluate its possible applica-
tion as a scolicidal agent during surgery or puncture-aspiration-
injection-reaspiration (PAIR).
As was mentioned previously, TAM induces protection against
the in vivo establishment of T. solium and T. crassiceps (12, 13).
Although the conditions used in our experiments are different,
since E. granulosus is a tissue parasite, our results coincide. Pro-
tection against the infection was observed during the chemopro-
phylactic efficacy study. Furthermore, this study describes for the
first time the clinical efficacy of TAM for a cestode parasite.
After the oral administration of TAM to mice, the drug dem-
onstrated a chemoprophylactic effect. First, 20% of TAM-treated
mice did not develop any cysts, while the infection progressed in
all unmedicated mice. A deleterious drug effect on E. granulosus
protoscoleces at the time of infection may help to explain the lack
of cyst development. Additionally, statistically significant differ-
ences in cyst weight were detected between the treated and control
groups. Therefore, TAM may not only reduce the number of cysts
that develop but may also inhibit the development of secondary
hydatidosis in mice. It is important to highlight the fact that the
obtained results coincide with those for other treatment schedules
previously assayed (26, 27). SEM and TEM evaluations revealed
that TAM induces a number of characteristic alterations in the
cyst germinal layer. The ultrastructural changes induced by TAM
were similar to those described for other compounds such as al-
bendazole, praziquantel, and flubendazole (26, 27), including dis-
torted internal tissue, vacuolated areas, and the presence of abun-
dant lipid droplets.
Hydatid cysts developed in all of the infected animals involved
in the clinical efficacy studies. A clear reduction in cyst weight was
observed after the administration of TAM in mice with cysts that
developed during 3 or 6 months compared with that in the un-
medicated control mice (Fig. 5A). Not surprisingly, greater effec-
tiveness of the treatment was observed when TAM was adminis-
tered 3 months p.i. This coincides with the results obtained by
Urrea-París et al. (28), and a possible explanation is that the most
pronounced development of cystic layers might protect the cyst
against the drug. The germinal layer of cysts recovered from TAM-
treated mice was markedly altered. Nevertheless, the ultrastruc-
tural damage extension appeared to be greater when the drug was
administered earlier (3 months p.i.). Furthermore, when the dose
was increased (100 mg/kg), complete destruction of the germinal
layer was observed. Once again, the ultrastructural changes in-
duced by TAM were similar to those described for other drugs,
such as albendazole and flubendazole (21, 29, 30).
Despite the promising results, TAM has a parasitostatic rather
than parasiticidal effect, as is also the case for benzimidazoles (4).
Further studies should be conducted to focus on adjusting the
dose of TAM to obtain a parasiticidal effect.
TAM, due to its high lipid partition coefficient, has been shown
to be strongly incorporated in biomembranes (31). This TAM
incorporation is increased when the cholesterol concentration is
low. To be accurate, E. granulosus organisms do not synthesize
cholesterol, and the amount of this lipid is limited in their cell
membranes; thus, this aspect may favor accumulation of TAM in
the cells. Besides, TAM is a potent inhibitor of the Pgp efflux
transporter (32, 33). Our results in E. granulosus correlate well
with these findings (Fig. 1B and C). Thus, this TAM retention in
Echinococcus cells and cysts might enhance the pharmacological
effects (Fig. 1B and C and 4 and 5). Moreover, we demonstrated
that TAM and its metabolites were accumulated in the cysts in
adequate quantities after in vivo treatment of infected mice. Our
results coincide with the concentrations reported by Robinson et
al. (34) in mouse tissues.
Signaling pathways involving sterol-responsive nuclear recep-
tors are conserved from invertebrates to mammals and regulate
metabolism and development (35). Recent evidence revealed that
estrogens can affect Taenia physiology (13, 36). Within this line of
evidence, the efficiency of chemoprotective TAM treatment sug-
gests a possible role for the estrogens in Echinococcus develop-
ment. Interestingly, all NRs have been recently identified in E.
multilocularis andE. granulosus genomes, and one of them showed
the highest homology to the LBDs of vertebrate ER (17). In this
work, we verified in the E. granulosus larval stage the constitutive
expression of this putative SR, E. granulosus SR, an EmuJ_
000814300 ortholog, which displayed similarities in structure to
the H. sapiens ER and an invertebrate prototype ER (Fig. 6).
Furthermore, it has been proposed that during estrogen recep-
tor evolution, specificity has been determined by the early require-
ment for the aromatized A ring, the final step in a conserved es-
trogen synthesis pathway beginning with cholesterol (37).
Therein, a promiscuous ancestral SR is activated by nonsteroidal
ER agonists such as DES and genistein and competitively inhibited
by ER antagonists such as SERMs (37). Tapeworms, like flukes,
lack the ability to synthesize cholesterol de novo, and until now
there has been no conclusive research on the biosynthesis of es-
trogens, progesterone, and androgens in cestodes (17). Metabolic
and transcriptomic studies have demonstrated that sterol synthe-
sis in E. granulosus is interrupted at the level of farnesyl or nerol-
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idol pyrophosphate, that the cholesterol derives from the host,
and that for signaling actions, the host sterols may be modified by
the parasite (38). But it is highly likely that if Echinococcus spp.
have sensitivity to estrogens, the candidate receptor might be the
E. granulosus SR.
Calcium-dependent activation of H. sapiens ER is mediated by
CaM, and CaM antagonists prevent 17-estradiol from stimulat-
ing the transcription (39, 40). CaM binds to H. sapiens ER in the
hinge domain (residues 248 to 317) and contributes to the ER
dimerization and to the ER transcriptional activity in combina-
tion with 17-estradiol and calcium (39, 40). The E. granulosus SR
conserves this hydrophobic region in the LBD involved in associ-
ation with the CaM ER (Fig. 6) (40). On the other hand, in our
attempt to understand the TAM mechanism in E. granulosus, sev-
eral findings suggested that TAM interfered with calcium homeo-
stasis in eukaryotic cells (41). Different research on mammalian
cells and yeast clearly showed that TAM targets endoplasmic re-
ticulum calcium pumps, protein kinase C, and/or CaM. Conse-
quently, this targeting induces an increase in intracellular calcium
as a non-estrogen receptor-dependent effect (18). Our in vitro
results on the TAM effects suggest a calcium cell deregulation in
treated protoscoleces (Fig. 1A) through independent or indirectly
ER-dependent mechanisms, which must be confirmed by further
studies on the Echinococcus larval stage.
In the search for an effective drug against E. granulosus, we
showed that TAM, at low micromolar concentrations, inhibits the
survival of protoscoleces and metacestodes. Moreover, we dem-
onstrated the chemotherapeutic and chemopreventive pharmaco-
logical effects of TAM. Since the collateral effects of high TAM
doses have been largely documented in clinical trials, the use of
low doses of this drug as a short-term therapy may be a novel
alternative approach for human CE treatment. Nevertheless, this
is a preliminary study performed in a murine model, and for this
reason, more exhaustive evaluation should be carried out in hu-
mans to fully demonstrate the therapeutic usefulness of TAM.
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